$0.00—Stale · unknown old
OTCMARKET • Last print unknown ago
$0.00—Stale · unknown old
Affimed N.V. is a biotechnology company focused on developing immuno-oncology therapies, specifically utilizing its proprietary ROCK platform to create bispecific antibodies. The company's competitive position is bolstered by its innovative approach to harnessing the immune system to target cancer cells, with a focus on hematological malignancies and solid tumors.
Affimed generates revenue primarily through partnerships and licensing agreements with larger pharmaceutical companies, leveraging its proprietary technology to develop novel therapies. The company has a high gross margin due to the nature of its research and development-focused business model, although it currently operates at a significant loss due to high R&D expenditures.
Progress in clinical trials for lead candidates like AFM13 and AFM24
Partnership announcements or collaborations with larger pharmaceutical firms
Regulatory approvals for new therapies
Market sentiment towards the biotechnology sector
Regulatory changes impacting drug approval processes
Technological disruption from competing therapies or platforms
Increased competition from other biotech firms developing similar immuno-oncology therapies
Potential for larger pharmaceutical companies to out-license or develop competing products
High cash burn rate leading to potential liquidity issues
Dependence on external financing for ongoing R&D
low - The biotechnology sector is generally less sensitive to economic cycles, as demand for healthcare remains relatively stable regardless of economic conditions.
Interest rates can affect the company's cost of capital and funding for R&D, but given its current low revenue, the immediate impact on demand is minimal.
minimal - Affimed's operations are not heavily reliant on credit markets, although access to capital is necessary for ongoing R&D.
growth - Investors looking for high-risk, high-reward opportunities in the biotech sector.
high - The stock exhibits high volatility due to the binary nature of clinical trial outcomes and market sentiment.